Tango Therapeutics Inc (NASDAQ: TNGX) on Monday, plunged -6.49% from the previous trading day, before settling in for the closing price of $3.85. Within the past 52 weeks, TNGX’s price has moved between $2.70 and $13.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 132.62% over the past five years. The company achieved an average annual earnings per share of -11.20%. With a float of $59.92 million, this company’s outstanding shares have now reached $102.20 million.
Let’s look at the performance matrix of the company that is accounted for 140 employees. In terms of profitability, gross margin is 95.68%, operating margin of -322.0%, and the pretax margin is -283.95%.
Tango Therapeutics Inc (TNGX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tango Therapeutics Inc is 44.22%, while institutional ownership is 56.77%. The most recent insider transaction that took place on Nov 18 ’24, was worth 37,800. In this transaction Director of this company bought 10,000 shares at a rate of $3.78, taking the stock ownership to the 31,250 shares. Before that another transaction happened on Nov 14 ’24, when Company’s Director bought 10,000 for $3.62, making the entire transaction worth $36,200. This insider now owns 21,250 shares in total.
Tango Therapeutics Inc (TNGX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.3 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.27) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.20% per share during the next fiscal year.
Tango Therapeutics Inc (NASDAQ: TNGX) Trading Performance Indicators
Tango Therapeutics Inc (TNGX) is currently performing well based on its current performance indicators. A quick ratio of 8.00 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.17, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.43 in one year’s time.
Technical Analysis of Tango Therapeutics Inc (TNGX)
Tango Therapeutics Inc (NASDAQ: TNGX) saw its 5-day average volume 3.51 million, a positive change from its year-to-date volume of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 51.79%. Additionally, its Average True Range was 0.55.
During the past 100 days, Tango Therapeutics Inc’s (TNGX) raw stochastic average was set at 9.66%, which indicates a significant decrease from 27.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 217.50% in the past 14 days, which was higher than the 108.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.53, while its 200-day Moving Average is $8.49. Nevertheless, the first resistance level for the watch stands at $3.78 in the near term. At $3.96, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.08. If the price goes on to break the first support level at $3.48, it is likely to go to the next support level at $3.36. Assuming the price breaks the second support level, the third support level stands at $3.18.
Tango Therapeutics Inc (NASDAQ: TNGX) Key Stats
Market capitalization of the company is 379.80 million based on 107,418K outstanding shares. Right now, sales total 36,530 K and income totals -101,740 K. The company made 11,610 K in profit during its latest quarter, and -29,170 K in sales during its previous quarter.
